| scholarly article | Q13442814 |
| P50 | author | Martin Metz | Q37838546 |
| Marcus Maurer | Q50039778 | ||
| P2093 | author name string | Martin K Church | |
| Tse Wen Chang | |||
| Christina Chen | |||
| Chien-Jen Lin | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| urticaria | Q187440 | ||
| chronic spontaneous urticaria | Q102296062 | ||
| P1104 | number of pages | 6 | |
| P304 | page(s) | 337-342 | |
| P577 | publication date | 2014-06-17 | |
| P1433 | published in | The Journal of Allergy and Clinical Immunology | Q7743550 |
| P1476 | title | The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria | |
| P478 | volume | 135 |
| Q38682275 | A 63-year-old man with chronic spontaneous urticaria |
| Q26767461 | Advances in Understanding and Managing Chronic Urticaria |
| Q40812061 | Advances in anti-IgE therapy |
| Q42091038 | Anti-IgE Treatment for Disorders Other Than Asthma |
| Q93385043 | Anti-TPO IgE Autoantibody in Chronic Urticaria: Is It Clinically Relevant? |
| Q40690949 | Atopic predisposition in cholinergic urticaria patients and its implications |
| Q38942933 | Autoreactive IgE in Chronic Spontaneous/Idiopathic Urticaria and Basophil/Mastocyte Priming Phenomenon, as a Feature of Autoimmune Nature of the Syndrome. |
| Q90398003 | Chronic Spontaneous Urticaria: The Devil's Itch |
| Q58418332 | Chronic spontaneous urticaria: immune system, blood coagulation, and more |
| Q90380732 | Chronic urticaria and thyroid pathology |
| Q40989403 | Chronic urticaria: a focus on pathogenesis |
| Q33588223 | Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin |
| Q38627179 | Comorbidity and pathogenic links of chronic spontaneous urticaria and systemic lupus erythematosus--a systematic review |
| Q38751342 | Current and future therapies for treating chronic spontaneous urticaria |
| Q38547047 | Current challenges and controversies in the management of chronic spontaneous urticaria |
| Q91636358 | Designation of Autoinflammatory Skin Manifestations With Specific Genetic Backgrounds |
| Q47783261 | Disease-specific impairment of the quality of life in adult patients with chronic spontaneous urticaria |
| Q48256384 | Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients |
| Q92373370 | Effective treatment of different H1-antihistamine-refractory chronic urticaria phenotypes with omalizumab |
| Q37092944 | Elevated Plasma Level of Interferon-λ1 in Chronic Spontaneous Urticaria: Upregulated Expression in CD8(+) and Epithelial Cells and Induction of Inflammatory Cell Accumulation. |
| Q36870053 | Evolution of anti-IgE treatment |
| Q38793428 | From IgE to Omalizumab |
| Q26743369 | Guideline of Chronic Urticaria Beyond |
| Q39003567 | Idiopathic Non-histaminergic Angioedema: Successful Treatment with Omalizumab in Five Patients. |
| Q47602330 | IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review |
| Q52804420 | Immunoglobulin E-Mediated Autoimmunity. |
| Q92381291 | Increased Plasma Levels of S100A8, S100A9, and S100A12 in Chronic Spontaneous Urticaria |
| Q33683786 | Increased cis-to-trans urocanic acid ratio in the skin of chronic spontaneous urticaria patients |
| Q38709401 | Long-term management of chronic spontaneous urticaria with omalizumab |
| Q52938044 | Management and treatment of chronic urticaria (CU). |
| Q52866200 | Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series. |
| Q46701587 | Mast cells are critical for the limitation of thrombin-induced skin inflammation |
| Q39012896 | Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria |
| Q41482365 | Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells |
| Q90108933 | Omalizumab for Aspirin-Hypersensitivity and Leukotriene Overproduction in Aspirin-Exacerbated Respiratory Disease: A Randomized Trial |
| Q90353307 | Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice |
| Q52976551 | Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. |
| Q38754492 | Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature. |
| Q34604574 | Omalizumab in children |
| Q48199854 | Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. |
| Q38574776 | Omalizumab therapy for children and adolescents with severe allergic asthma. |
| Q38248806 | Omalizumab: a review of its use in patients with chronic spontaneous urticaria |
| Q39122684 | Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses |
| Q42386255 | Perip7lakin is a target for autoimmunity in asthma. |
| Q28073074 | Personalized Medicine in Allergy |
| Q26783158 | Profile of omalizumab in the treatment of chronic spontaneous urticaria |
| Q38450662 | Role of biologics in intractable urticaria |
| Q53733505 | Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab. |
| Q38585084 | Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU). |
| Q36016733 | Serum Clusterin as a Prognostic Marker of Chronic Spontaneous Urticaria |
| Q35783662 | Structural and Physical Basis for Anti-IgE Therapy |
| Q41690158 | Systemic contact dermatitis caused by cobalt chloride and palladium in a 26-year-old woman with allergic type I reactions, non-steroidal anti-inflammatory drug hypersensitivity and autoimmune thyroiditis |
| Q48104058 | The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change. |
| Q59793790 | The overlap syndrome of urticaria and gastroesophageal reflux disease |
| Q38811111 | Treating IgE-mediated diseases via targeting IgE-expressing B cells using an anti-CεmX antibody |
| Q59135496 | Two decades with omalizumab: what we still have to learn |
| Q38970557 | Update on Potential Therapies for IgE-Mediated Food Allergy |
| Q90734618 | Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020 |
| Q38682862 | Use of nonbiologic treatments in antihistamine-refractory chronic urticaria: a review of published evidence |
Search more.